Market Research Logo

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

REPORT HIGHLIGHTS

The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.

This report provides:

An overview of the global markets and technologies for cancer vaccines.

Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.

Coverage of the cancer vaccines arena including diverse therapeutic platform technologies, immune-stimulating agents and approved vaccines for cancer.

Examination of the governmental and regulatory environment and how its effecting the market.

Information on new developments including products in Phase I-IV clinical trials, as well as new technologies.

Analysis of the market's dynamics, specifically growth and restriction factors, acquisitions and collaborations, and a look at the cancer vaccine market's current achievements and future challenges.

Relevant patent analysis, presented by year and by vaccine type.


SCOPE OF THE STUDY

The scope of this study entails the current the market for cancer vaccines, which includes therapeutic cancer vaccines and preventive cancer vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines are also included; however, while such vaccines only indirectly act against cancer, they do aid in reducing the global cancer burden. The report also includes regulatory aspects, current and developing technologies, the demographics of cancer incidence, innovation and challenges, patent analyses, market projections and market share, along with latest trends and clinical trials.

Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis. Product information and the technologies/platforms discussed in the report are based on their present and prospective application and practicality. The report presents sales analyses broken down geographically for the United States, Europe and the emerging markets. The emerging markets include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of cancer vaccines in various types of cancer is discussed from both commercial perspective and that of a research and development (R&D) perspective.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITIONS
HISTORY OF CANCER AND ITS MANAGEMENT
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT
CLASSIFICATION OF CANCERS
CLASSIFICATION BY SITE OF ORIGIN
CLASSIFICATION BY TISSUE TYPE
Carcinoma
Adenocarcinoma
Squamous Cell Carcinoma
Sarcomas
Myeloma
Leukemias
Lymphomas
Mixed Types
CLASSIFICATION BY GRADE
SYMPTOMS OF CANCER
LOCAL SYMPTOMS
SYSTEMIC SYMPTOMS
SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS
RISK FACTORS
CANCER-CAUSING AGENTS
CHEMICAL CARCINOGENS
IONIZING RADIATION
VIRAL AND BACTERIAL INFECTIONS
GENETIC OR INHERITED CANCERS
HORMONAL CHANGES
IMMUNE SYSTEM DYSFUNCTION
COMMERCIALLY AVAILABLE CANCER VACCINES
LIVER CANCER
PROSTATE CANCER
Radical Retropubic Prostatectomy
Laparoscopic Prostatectomy
Radical Perineal Prostatectomy
Transurethral Resection of the Prostate
CERVICAL CANCER
PREVALENCE
TABLE 2 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)
INCIDENCE AND MORTALITY RATE
TABLE 3 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012
CANCER STATISTICS BY GEOGRAPHY
TABLE 4 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
TABLE 5 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012
GLOBAL CANCER STATISTICS BY TYPE OF CANCER
TABLE 6 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)
TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)
TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)
VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY
TABLE 9 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012
TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012
TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012
CANCER AND THE IMMUNE SYSTEM
MOLECULAR BIOLOGY OF CANCER
CANCER PATHOPHYSIOLOGY
ONCOGENES
TUMOR SUPPRESSOR GENES
PREVENTION OF CANCER
MANAGEMENT OF CANCER
SURGERY
CHEMOTHERAPY
RADIATION THERAPY
TARGETED THERAPY
IMMUNOTHERAPY
HORMONAL THERAPY
BIOLOGICAL THERAPY
CANCER VACCINES
CLASSIFICATION OF CANCER VACCINES
Preventive (or Prophylactic) Vaccines
Therapeutic Vaccines
MANUFACTURING/CREATING VACCINES
TYPES OF CANCER VACCINES
Tumor Cell Vaccines
Cancer Stem Cell Vaccines
Peptide/Protein Vaccines
Antigen Vaccines
Anti-idiotype Vaccines
Heat Shock Protein Vaccines
DNA and Vector-Based Vaccines
CHAPTER 4 REGULATORY ASPECTS
REGULATORY HISTORY OF APPROVED CANCER VACCINES
TABLE 12 REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014
RECALLS
TABLE 13 PRODUCT RECALLS, JAN. 2010 TO JULY 2014
ORPHAN DRUG DESIGNATION
TABLE 14 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014
OTHER SIGNIFICANT REGULATORY ASPECTS
CHAPTER 5 NEW DEVELOPMENTS
PROSTATE CANCER
TABLE 15 CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.)
TABLE 16 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT
BREAST CANCER
TABLE 17 CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.)
TABLE 18 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT
CERVICAL CANCER
TABLE 19 CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.)
TABLE 20 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT
LIVER CANCER
TABLE 21 CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.)
TABLE 22 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT
LUNG CANCER
TABLE 23 CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.)
TABLE 24 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER
STOMACH CANCER
TABLE 25 CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.)
TABLE 26 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT
COLORECTAL CANCER
TABLE 27 CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.)
TABLE 28 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT
ESOPHAGEAL CANCER
TABLE 29 CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.)
TABLE 30 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT
CHAPTER 6 MARKET ANALYSIS OF CANCER VACCINES
MARKET BY TYPE
MARKET OVERVIEW
MARKET REVENUES
TABLE 31 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 ($ MILLIONS)
MARKET SHARES
TABLE 32 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
FIGURE 2 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 (%)
MARKET BY REGION
MARKET OVERVIEW
MARKET REVENUES
TABLE 33 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
THERAPEUTIC VACCINES
Market Overview
Market Revenues
TABLE 34 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 ($ MILLIONS)
Market Shares
TABLE 35 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
FIGURE 5 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 (%)
PROPHYLACTIC VACCINES
Market Overview
Market Revenues
TABLE 36 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
Market Shares
TABLE 37 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
FIGURE 7 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 (%)
INDUSTRY STRUCTURE
PROPHYLACTIC CANCER VACCINES
Market Leaders
TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013
Market Shares
TABLE 39 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
FIGURE 8 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 (%)
THERAPEUTIC CANCER VACCINES
Market Leader
TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013
Market Share
TABLE 41 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)
FIGURE 9 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 (%)
CHAPTER 7 MARKET BY CANCER TYPE
GLOBAL MARKET BY CANCER TYPE
MARKET REVENUES
TABLE 42 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 ($ MILLIONS)
MARKET SHARES
TABLE 43 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
FIGURE 11 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 (%)
PROSTATE CANCER
Market Overview
Market Revenues
TABLE 44 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 ($ MILLIONS)
LIVER CANCER
Market Overview
Market Revenues
TABLE 45 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
CERVICAL CANCER VACCINES
Market Overview
Market Revenues
TABLE 46 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 ($ MILLIONS)
CHAPTER 8 PATENT ANALYSIS
PATENTS BY YEAR
TABLE 47 SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.)
FIGURE 15 SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.)
PATENTS BY TYPE/CATEGORY
TABLE 48 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
FIGURE 16 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.)
PATENTS BY COMPANY
TABLE 49 U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.)
PATENTS BY PATENT HOLDER'S COUNTRY
TABLE 50 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
FIGURE 17 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.)
TABLE 51 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
FIGURE 18 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (%)
PATENTS BY ASSIGNEE TYPE
TABLE 52 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)
FIGURE 19 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.)
CHAPTER 9 CURRENT SITUATION
FACTORS AFFECTING CANCER VACCINES
INCREASING PREVALENCE OF CANCER
AGING POPULATION
LIFESTYLE CHANGES
APPROVALS FOR ADDITIONAL INDICATIONS
COMPETITION
MANUFACTURERS' STRATEGIES
CHAPTER 10 COMPANY PROFILES
ADAMIS PHARMACEUTICALS CORP.
ADURO BIOTECH INC.
ADVANTAGENE INC.
ADVAXIS INC.
ALPHAVAX HUMAN VACCINES INC.
ALTOR BIOSCIENCE CORP.
ANTIGEN EXPRESS INC.
BAVARIAN NORDIC A/S
BELLICUM PHARMACEUTICALS
BIOVEST INTERNATIONAL
CELLDEX THERAPEUTICS
CUREVAC GMBH
DENDREON
EMD SERONO
GALINA BIOPHARMA
GENEXINE INC.
GLAXOSMITHKLINE
GLOBEIMMUNE INC.
GRADALIS INC.
HEAT BIOLOGICS INC.
IMMUNE CELL THERAPY INC. (ICT)
IMMUNICUM
IMMUNOFRONTIER INC.
IMMUNOVATIVE THERAPIES LTD.
INOVIO PHARMACEUTICALS
ISA PHARMACEUTICALS
KAEL-GEMVAX CO. LTD.
MERCK & CO.
NEWLINK GENETICS CORP.
NOVARX CORP.
ONCOTHYREON
ONCOVIR INC
OXFORD BIOMEDICA
SOTIO AS
UBIVAC LLC
VICAL INC.
VACCINOGEN INC.
VAXON BIOTECH
CHAPTER 11 ACRONYMS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report